Zalicus | ZLCS : NASDAQ : US$1.38 Buy , Target US$3.00 New Exalgo dose to expand market opportunity; Synavive data just around the corner Investment recommendation Reiterate BUY, $3 target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions [...]![]()
